Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113620 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy
A Phase 3 study of Pain and Diabetic Neuropathy, sponsored by Avanir Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT00113620: Completed Phase 3 study of Pain and Diabetic Neuropathy, sponsored by Avanir Pharmaceuticals.
NCT00113620 is a Phase 3 study of Pain and Diabetic Neuropathy that has completed, run by Avanir Pharmaceuticals. The registered enrollment target is 450 participants, above the 303-participant average among 374 other Pain trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00113620, a Phase 3 study of Pain and Diabetic Neuropathy, has completed, sponsored by Avanir Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether dextromethorphan (Neurodex) and quinidine are effective in the treatment of pain of diabetic neuropathy.
Conditions Studied
Interventions
- DRUG Neurodex
Study Locations (20)
Florida
- Tampa Bay Medical Research - Clearwater
- University Clinical Research - DeLand - DeLand
- The Center for Diabetes and Endocrine Care - Hollywood
- FPA Clinical Research - Kissimmee
- Suncoast Neuroscience Associates, Inc. - St. Petersburg
- Neurology Clinical Research, Inc. - Sunrise
- Laszlo J. Mate, MD - West Palm Beach
California
- Bay Area Foot Care - Castro Valley
- South Bay Clinical Research Inc. - Inglewood
- Pacific Sleep Medicine Services, Inc. - Los Angeles
- Pacific Sleep Medicine Services, Inc. - Palm Springs
- Northern California Research Group - Sacramento
- Diablo Clinical Research, Inc. - Walnut Creek
Arizona
- Pivotal Research Centers - Mesa
- Dedicate Clinical Research, Inc. - Sun City
Arkansas
- Central Arkansas Research - Hot Springs
- Research Solutions - Jonesboro
Indiana
- Medisphere Medical Research Center, LLC - Evansville
- Investigative Clinical Reserach of Indiana, LLC - Indianapolis
Hawaii
- East-West Medical Research Institute - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2005-07 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
What the finished NCT00113620 record still lists
NCT00113620 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, above the 303-participant average among 374 other Pain trials with a reported enrollment target (49% higher).
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 1 intervention - of which Neurodex is the first listed.
NCT00113620 names 20 study sites across 6 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00113620 about?
NCT00113620 is a clinical study titled "Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy". The purpose of this study is to determine whether dextromethorphan (Neurodex) and quinidine are effective in the treatment of pain of diabetic neuropathy.
What is the current status of trial NCT00113620?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2005-07. Estimated completion is 2007-02.
What conditions does trial NCT00113620 study?
This clinical trial studies the following conditions: Pain, Diabetic Neuropathy.
What interventions are being tested in trial NCT00113620?
The interventions under investigation include: Neurodex (DRUG).
Who is sponsoring clinical trial NCT00113620?
This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00113620 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00113620's enrollment target sits among peer trials
450 40th of 374 higher than 333 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial
RECRUITING · Phase 3
-
Opioid-Free Orthopaedics
RECRUITING · Phase 3
-
Suzetrigine in Total Hip Arthroplasty
RECRUITING · Phase 3
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
- NCT04165070 · 450 participants · Phase 1
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia